ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors

Conclusions: Our findings demonstrate that while over-expression of Met is not predictive of Met-directed TKI response, immunoPET can detect Met over-expression in vivo and predicts for therapeutic response to Met-selective RLT. This phenomenon can be exploited for other Met-overexpressing tumor types specifically, and to any differentially overexpressed surface molecule more broadly.

Source: Theranostics - July 3, 2020 Category: Molecular Biology Authors: Freddy E. Escorcia, Jacob L. Houghton, Dalya Abdel-Atti, Patricia R. Pereira, Andrew Cho, Nicholas T. Gutsche, Kwamena E. Baidoo, Jason S. Lewis Tags: Research Paper Source Type: research